Ignoring the FDA and just looking at the numbers .
Co says they have $135 m in cash 9/30 . If they can keep their cash burn to $15m a Qt they go into 2015 with $120m. Reduce it costs will be declining as almost fully enrolled ..so they could get to 2016 with more then $60m cash on hand
You have to think that some one or Co will fund this at least to interim analysis .
For those that like high spec positions , can handle a drop to $60c a share if they dilute , are only using $ they can afford to loose and are patient ...at 90c a share ..its an interesting spec play